On October 21, 2019, Harbin Pharmaceutical Group announced that its subsidiary, Harbin Pharmaceutical Group Sixth Pharmaceutical Factory (hereinafter referred to as “Harbin Sixth Pharmaceutical Factory”), had successfully passed the consistency evaluation for the quality and efficacy of its generic metformin hydrochloride tablets. The product received the “Supplemental Application Approval Document” issued by the National Medical Products Administration.

Guangzhou DiQi Pharmaceuticals Co., Ltd (hereinafter referred to as “DiQi Pharmaceuticals Co., Ltd”) extends its heartfelt congratulations as the pharmaceutical research and technical service provider for Harbin Pharmaceutical Group No. 6 Factory's Metformin Hydrochloride Tablets project!

Over the past two years, DiQi Pharmaceuticals Co., Ltd has provided pharmaceutical research services for Guangdong South China Pharmaceutical, Shenzhen Zhonglian Pharmaceutical, and Guizhou Tian'an Pharmaceutical. Their metformin hydrochloride tablets (0.25g) have successively passed the consistency evaluation for quality and efficacy of generic drugs. Harbin Pharmaceutical Factory No. 6 marks the fourth manufacturer served by DiQi Pharmaceuticals Co., Ltd to pass the consistency evaluation for Metformin Hydrochloride Tablets (0.25g), and the second manufacturer exempted from on-site production inspection. This demonstrates the full recognition by the Drug Evaluation Center of the authenticity, completeness, and scientific rigor of the pharmaceutical submission documents prepared by our company. DiQi Pharmaceuticals Co., Ltd extends its gratitude to our partners for their continued trust and support! We extend our gratitude to every member of the DiQi team for their hard work and dedication to pharmaceutical R&D!